Gemma E. Seabright
Southampton, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Glycan heterogeneity as a cause of the persistent fraction in HIV-1 neutralization.
Journal: PLoS pathogens
Published: August 07, 2023
A cross-neutralizing antibody between HIV-1 and influenza virus.
Journal: PLoS pathogens
Published: September 21, 2020
Effector function does not contribute to protection from virus challenge by a highly potent HIV broadly neutralizing antibody in nonhuman primates.
Journal: Science translational medicine
Published: September 01, 2020
Enhancing glycan occupancy of soluble HIV-1 envelope trimers to mimic the native viral spike.
Journal: Cell reports
Published: July 22, 2020
Vulnerabilities in coronavirus glycan shields despite extensive glycosylation.
Journal: Nature communications
Published: February 11, 2020
Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability.
Journal: Immunity
Published: July 15, 2019
Networks of HIV-1 Envelope Glycans Maintain Antibody Epitopes in the Face of Glycan Additions and Deletions.
Journal: Structure (London, England : 1993)
Published: May 13, 2019
Protein and Glycan Mimicry in HIV Vaccine Design.
Journal: Journal of molecular biology
Published: February 11, 2019
Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes.
Journal: Journal of virology
Published: September 19, 2018
Structure of the Lassa virus glycan shield provides a model for immunological resistance.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: June 27, 2018
Last Updated: 09/26/2026